Estrogen receptor genotypes, menopausal status, and the effects of tamoxifen on lipid levels

Revised and updated results

D. F. Hayes, Todd Skaar, J. M. Rae, N. L. Henry, A. T. Nguyen, V. Stearns, L. Li, S. Philips, Zeruesenay Desta, D. A. Flockhart

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

We previously reported that the ESR1 XbaI genotypes were associated with baseline and tamoxifen-induced serum lipid profiles. The analysis in that study was carried out by PCR followed by restriction-enzyme digestion. After reanalysis using more robust TaqMan assays, the findings related to ∼10% of the genotypes for the ESR1 XbaI single-nucleotide polymorphism (SNP) were revised. For the other genotypes (i.e., ESR1 PvuII, ESR2, and CYP2D6), the results were nearly identical to those in the previous study. Upon reanalysis, previously reported associations between the ESR1 Xba1 genotypes and baseline triglyceride and low-density lipoprotein (LDL) cholesterol levels were no longer observed. Previously reported associations between the ESR1 XbaI genotypes and tamoxifen-induced changes in levels of total cholesterol, triglycerides, and high-density lipoprotein (HDL) cholesterol were also no longer observed. However, the following observations from the original report did not change: (i) the levels of circulating lipids are lower in women taking tamoxifen; (ii) there is an association between the ESR2-02 genotypes and changes in triglyceride levels; and (iii) neither ESR1 PvuII nor CYP2D6 is associated with any changes in serum lipid concentrations in patients receiving treatment with tamoxifen.

Original languageEnglish
Pages (from-to)626-629
Number of pages4
JournalClinical Pharmacology and Therapeutics
Volume88
Issue number5
DOIs
StatePublished - Nov 2010

Fingerprint

Tamoxifen
Estrogen Receptors
Genotype
Lipids
Cytochrome P-450 CYP2D6
Triglycerides
Serum
LDL Cholesterol
HDL Cholesterol
Single Nucleotide Polymorphism
Digestion
Cholesterol
Polymerase Chain Reaction
Enzymes

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Medicine(all)

Cite this

Estrogen receptor genotypes, menopausal status, and the effects of tamoxifen on lipid levels : Revised and updated results. / Hayes, D. F.; Skaar, Todd; Rae, J. M.; Henry, N. L.; Nguyen, A. T.; Stearns, V.; Li, L.; Philips, S.; Desta, Zeruesenay; Flockhart, D. A.

In: Clinical Pharmacology and Therapeutics, Vol. 88, No. 5, 11.2010, p. 626-629.

Research output: Contribution to journalArticle

Hayes, D. F. ; Skaar, Todd ; Rae, J. M. ; Henry, N. L. ; Nguyen, A. T. ; Stearns, V. ; Li, L. ; Philips, S. ; Desta, Zeruesenay ; Flockhart, D. A. / Estrogen receptor genotypes, menopausal status, and the effects of tamoxifen on lipid levels : Revised and updated results. In: Clinical Pharmacology and Therapeutics. 2010 ; Vol. 88, No. 5. pp. 626-629.
@article{ea360a617bc44f37b0aa4e038763a64d,
title = "Estrogen receptor genotypes, menopausal status, and the effects of tamoxifen on lipid levels: Revised and updated results",
abstract = "We previously reported that the ESR1 XbaI genotypes were associated with baseline and tamoxifen-induced serum lipid profiles. The analysis in that study was carried out by PCR followed by restriction-enzyme digestion. After reanalysis using more robust TaqMan assays, the findings related to ∼10{\%} of the genotypes for the ESR1 XbaI single-nucleotide polymorphism (SNP) were revised. For the other genotypes (i.e., ESR1 PvuII, ESR2, and CYP2D6), the results were nearly identical to those in the previous study. Upon reanalysis, previously reported associations between the ESR1 Xba1 genotypes and baseline triglyceride and low-density lipoprotein (LDL) cholesterol levels were no longer observed. Previously reported associations between the ESR1 XbaI genotypes and tamoxifen-induced changes in levels of total cholesterol, triglycerides, and high-density lipoprotein (HDL) cholesterol were also no longer observed. However, the following observations from the original report did not change: (i) the levels of circulating lipids are lower in women taking tamoxifen; (ii) there is an association between the ESR2-02 genotypes and changes in triglyceride levels; and (iii) neither ESR1 PvuII nor CYP2D6 is associated with any changes in serum lipid concentrations in patients receiving treatment with tamoxifen.",
author = "Hayes, {D. F.} and Todd Skaar and Rae, {J. M.} and Henry, {N. L.} and Nguyen, {A. T.} and V. Stearns and L. Li and S. Philips and Zeruesenay Desta and Flockhart, {D. A.}",
year = "2010",
month = "11",
doi = "10.1038/clpt.2010.143",
language = "English",
volume = "88",
pages = "626--629",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Estrogen receptor genotypes, menopausal status, and the effects of tamoxifen on lipid levels

T2 - Revised and updated results

AU - Hayes, D. F.

AU - Skaar, Todd

AU - Rae, J. M.

AU - Henry, N. L.

AU - Nguyen, A. T.

AU - Stearns, V.

AU - Li, L.

AU - Philips, S.

AU - Desta, Zeruesenay

AU - Flockhart, D. A.

PY - 2010/11

Y1 - 2010/11

N2 - We previously reported that the ESR1 XbaI genotypes were associated with baseline and tamoxifen-induced serum lipid profiles. The analysis in that study was carried out by PCR followed by restriction-enzyme digestion. After reanalysis using more robust TaqMan assays, the findings related to ∼10% of the genotypes for the ESR1 XbaI single-nucleotide polymorphism (SNP) were revised. For the other genotypes (i.e., ESR1 PvuII, ESR2, and CYP2D6), the results were nearly identical to those in the previous study. Upon reanalysis, previously reported associations between the ESR1 Xba1 genotypes and baseline triglyceride and low-density lipoprotein (LDL) cholesterol levels were no longer observed. Previously reported associations between the ESR1 XbaI genotypes and tamoxifen-induced changes in levels of total cholesterol, triglycerides, and high-density lipoprotein (HDL) cholesterol were also no longer observed. However, the following observations from the original report did not change: (i) the levels of circulating lipids are lower in women taking tamoxifen; (ii) there is an association between the ESR2-02 genotypes and changes in triglyceride levels; and (iii) neither ESR1 PvuII nor CYP2D6 is associated with any changes in serum lipid concentrations in patients receiving treatment with tamoxifen.

AB - We previously reported that the ESR1 XbaI genotypes were associated with baseline and tamoxifen-induced serum lipid profiles. The analysis in that study was carried out by PCR followed by restriction-enzyme digestion. After reanalysis using more robust TaqMan assays, the findings related to ∼10% of the genotypes for the ESR1 XbaI single-nucleotide polymorphism (SNP) were revised. For the other genotypes (i.e., ESR1 PvuII, ESR2, and CYP2D6), the results were nearly identical to those in the previous study. Upon reanalysis, previously reported associations between the ESR1 Xba1 genotypes and baseline triglyceride and low-density lipoprotein (LDL) cholesterol levels were no longer observed. Previously reported associations between the ESR1 XbaI genotypes and tamoxifen-induced changes in levels of total cholesterol, triglycerides, and high-density lipoprotein (HDL) cholesterol were also no longer observed. However, the following observations from the original report did not change: (i) the levels of circulating lipids are lower in women taking tamoxifen; (ii) there is an association between the ESR2-02 genotypes and changes in triglyceride levels; and (iii) neither ESR1 PvuII nor CYP2D6 is associated with any changes in serum lipid concentrations in patients receiving treatment with tamoxifen.

UR - http://www.scopus.com/inward/record.url?scp=77958474560&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77958474560&partnerID=8YFLogxK

U2 - 10.1038/clpt.2010.143

DO - 10.1038/clpt.2010.143

M3 - Article

VL - 88

SP - 626

EP - 629

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 5

ER -